Latest News on ARQT

Financial News Based On Company


Advertisement
Advertisement

Director Howard Welgus proposes selling 4,728 Arcutis (ARQT) shares around November 16.

https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-8ac5e0c11fca.html
Arcutis Biotherapeutics, Inc. director Howard Welgus has proposed selling 4,728 common shares of the company, with an approximate sale date of November 16, 2026, and an aggregate market value of $133,140.48. This proposed sale is part of a Rule 10b5-1 plan adopted on March 13, 2026, and includes shares acquired through restricted-stock vesting and stock-option exercises. Welgus also reported previous sales of similar share amounts in September and October 2026.

Form 144 Arcutis Biotherapeutics For: 15 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-arcutis-biotherapeutics-for-15-november-93CH-5705274
This article from Investing.com announces the filing of Form 144 for Arcutis Biotherapeutics on November 15, 2026. Form 144 indicates an intent to sell restricted or control securities. The article provides the title and date of the filing without further details about the transaction.

Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting

https://www.quantisnow.com/insight/arcutis-presents-new-caregiver-reported-outcomes-data-supporting-zoryve-roflumilast-cream-6789620
Arcutis Biotherapeutics presented new caregiver-reported data from the INTEGUMENT-INFANT trial at the ACAAI annual meeting, demonstrating that ZORYVE cream 0.05% improved itch and quality of life in infants with mild to moderate atopic dermatitis. This data supports a supplemental New Drug Application (sNDA) currently under FDA review for infants as young as 3 months, with a target action date of February 23, 2027. While positive clinical evidence for a pending label expansion, the sNDA is not yet approved and is subject to FDA review.

New data shows ZORYVE cream improves symptoms and quality of life in infants with mild to moderate atopic dermatitis.

https://pluang.com/en/news-feed/arcutis-data-pendukung-zoryve-krim-bayi-dermatitis-atopik
Arcutis Biotherapeutics presented new caregiver-reported data from the INTEGUMENT-INFANT trial, indicating that ZORYVE (roflumilast) cream 0.05% significantly improves itch, symptoms, and quality of life in infants aged 3 to 24 months with mild to moderate atopic dermatitis. The cream was well tolerated, with no serious adverse events reported. These findings support Arcutis's supplemental FDA application to expand ZORYVE's use to younger infants, addressing a critical need for safe, steroid-free treatment options in this vulnerable population.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/11/07/tmt-newswire/globenewswire/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2464333
Arcutis Biotherapeutics, Inc. announced the grant of 58,500 restricted stock units and options to purchase 17,000 shares to six new employees. These inducement grants were made under the company's 2022 Inducement Plan, with a grant date of November 2, 2026, and are subject to vesting schedules over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and an exercise price of $31.26 per share, matching the closing price on November 2, 2026.
Advertisement

Arcutis Biotherapeutics (ARQT) Returns To Profit, Is The Premium Already Priced In?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-returns-to-profit-is-the-premiu
Arcutis Biotherapeutics (ARQT) has returned to profitability with third-quarter 2026 revenue of US$143.92 million and net income of US$8.8 million. The stock has seen significant momentum, with a 42.35% return in one month, though its current Price-to-Sales (P/S) ratio of 9.2x suggests it may be overvalued compared to peers. However, a Discounted Cash Flow (DCF) model indicates the stock could be trading at a materially lower level than its estimated future cash flow value.

A new study will test an eczema cream in people as young as 6 with moderate to severe disease.

https://www.stocktitan.net/news/ARQT/arcutis-begins-enrolling-phase-3-study-evaluating-zoryve-roflumilast-lz6h8hocvto7.html
Arcutis Biotherapeutics has begun enrolling participants in its Phase 3 INTEGUMENT-3 trial, evaluating ZORYVE cream 0.3% for moderate to severe atopic dermatitis in individuals aged 6 and older. The study aims to expand ZORYVE's indication beyond mild to moderate cases, assessing its safety and efficacy over a 4-week double-blind period, with a 48-week open-label extension. This initiative seeks to provide an additional treatment option for patients experiencing significant disease burden from more severe forms of atopic dermatitis.

Arcutis Biotherapeutics, Inc. (ARQT) options chain

https://au.finance.yahoo.com/quote/ARQT/options/?date=1792108800&straddle=false&type=all
This article from Yahoo Finance provides information on the options chain for Arcutis Biotherapeutics, Inc. (ARQT). It shows that there are currently no calls or puts listed for the company, indicating limited options trading activity. The page also displays the stock's real-time price, recent performance, and a replay option for the Q3 2026 earnings call.

Arcutis earnings on deck: Can Zoryve growth offset seasonal drag?

https://www.investing.com/news/earnings/arcutis-earnings-on-deck-can-zoryve-growth-offset-seasonal-drag-93CH-5000504
Arcutis Biotherapeutics is set to report third-quarter earnings, with analysts expecting 18 cents per share on $141.9 million revenue. Investors will be monitoring whether the growth of its flagship Zoryve franchise can counteract typical seasonal slowdowns in prescription volumes. Key areas of focus include Zoryve's prescription trajectory, the impact of a recent salesforce expansion, and gross-to-net trends to assess pricing power and reimbursement stability.

Form 4 Arcutis Biotherapeutics Inc: Masaru Matsuda (EVP, Chief Legal Officer) For: 2 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-masaru-matsuda-evp-chief-legal-officer-for-2-november-93CH-5681542
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc., specifically detailing transactions by Masaru Matsuda, the EVP and Chief Legal Officer, on November 2nd. The filing indicates insider trading activity for the company, Arcutis Biotherapeutics (ARQT).
Advertisement

Arcutis Biotherapeutics EVP, CMO, sells $30,047 in shares

https://www.investing.com/news/insider-trading-news/arcutis-biotherapeutics-evp-cmo-sells-30047-in-shares-93CH-5002052
Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold 943 shares worth $30,047 to cover tax obligations from vested restricted stock units. This transaction occurred as the company's shares are trading near a 52-week high, having gained 45% in the last six months, though InvestingPro analysis suggests the stock is slightly overvalued. The company recently reported mixed Q3 2026 results, exceeding revenue expectations due to strong ZORYVE demand but missing profit forecasts due to heavy spending.

Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $39.62, Implies 16% Upside

https://www.tradingview.com/news/tradingview:4d3f2ba815353:0-arcutis-biotherapeutics-inc-stock-12-month-price-target-raised-to-39-62-implies-16-upside/
Arcutis Biotherapeutics, Inc. (ARQT) has seen its average 12-month price target raised from $39.12 to $39.62 by 8 analysts, implying a 16% potential upside from its Nov. 4 closing price. The consensus rating for the stock remains a "Buy," with 7 Buys and 1 Hold among covering analysts.

Commercial chief Robert Lisicki reports a 55,000-share stock award at Arcutis (ARQT).

https://www.stocktitan.net/sec-filings/ARQT/form-3-arcutis-biotherapeutics-inc-initial-statement-of-beneficial-ow-5792418f55e4.html
Robert Lisicki, EVP and Chief Commercial Officer at Arcutis Biotherapeutics, Inc., reported a direct holding of 55,000 common shares represented by Restricted Stock Units (RSUs) and options covering 145,000 common shares as of November 4, 2026. The RSUs and options are subject to continued service, with specific vesting schedules and an option exercise price of $25.61. This initial statement of beneficial ownership was filed with the SEC.

Arcutis Biotherapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62900354/arcutis-biotherapeutics-q3-2026-earnings-call-transcript
Arcutis Biotherapeutics reported robust Q3 2026 financial results with net product revenues of $143.9 million, a 45% increase year-over-year, and raised its full-year revenue guidance. The company is advancing its 'Grow, Expand, and Build' strategy, including a new awareness campaign for ZORYVE with Simone Biles, and expanding ZORYVE's indications through clinical trials for moderate to severe atopic dermatitis, vitiligo, and hidradenitis suppurativa. Arcutis is also strategically deploying AI across over 30 use cases to enhance efficiency and effectiveness in various business operations.

Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 EPS by 12c; Offers Guidance

https://www.streetinsider.com/Earnings/Arcutis+Biotherapeutics%2C+Inc.+%28ARQT%29+Misses+Q3+EPS+by+12c%3B+Offers+Guidance/27291702.html
Arcutis Biotherapeutics, Inc. (ARQT) reported a Q3 EPS of $0.06, missing analyst estimates by $0.12, though revenue of $143.9 million slightly beat the consensus. The company also provided its FY2026 revenue guidance, projecting between $535-545 million, which aligns closely with analyst expectations.
Advertisement

Agent fees may reach 3% as Arcutis (ARQT) may sell stock through TD Cowen.

https://www.stocktitan.net/sec-filings/ARQT/424b5-arcutis-biotherapeutics-inc-prospectus-supplement-debt-securiti-7c969e2d1de4.html
Arcutis Biotherapeutics, Inc. (ARQT) has entered into an agreement with TD Cowen to potentially sell up to $200 million in common stock through an "at-the-market" offering. TD Cowen's compensation for these sales may be up to 3.0% of the gross sales price. The proceeds are intended for general corporate purposes and the continued development and commercialization of the company's programs.

Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates

https://finance.yahoo.com/healthcare/articles/arcutis-biotherapeutics-inc-arqt-misses-211502100.html
Arcutis Biotherapeutics, Inc. (ARQT) reported Q3 earnings of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.17 per share, though revenues of $143.92 million surpassed expectations. Despite the earnings miss, the company's shares have gained 10.2% year-to-date, slightly underperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating an expectation of performing in line with the market.

Arcutis Biotherapeutics stock hits 52-week high at $33.30 By Investing.com

https://in.investing.com/news/stock-market-news/arcutis-biotherapeutics-stock-hits-52week-high-at-3330-93CH-5680514
Arcutis Biotherapeutics Inc. (ARQT) stock hit a new 52-week high of $33.30, reflecting a 36.05% increase over the past year. This surge is attributed to strong operational performance, including 76% revenue growth and a 91% gross profit margin, along with robust Q2 2026 revenue of $129.9 million driven by demand for its Zoryve product line. Analyst firms like Guggenheim and Jefferies have reiterated "Buy" ratings and raised price targets, underscoring positive market sentiment and future growth potential.

Form 144 Arcutis Biotherapeutics For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-arcutis-biotherapeutics-for-2-november-93CH-4923736
This article from Investing.com announces the filing of Form 144 for Arcutis Biotherapeutics on November 2nd. Form 144 indicates an intent to sell restricted or control securities. The article provides minimal detail beyond this announcement and includes a stock ticker for Arcutis Biotherapeutics (ARQT).

Form 144 Arcutis Biotherapeutics For: 2 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-arcutis-biotherapeutics-for-2-november-93CH-5673339
This article announces the filing of Form 144 for Arcutis Biotherapeutics on November 2nd. Form 144 is a notice of the intent to sell restricted securities. The article provides only this brief announcement without further details on the transaction.
Advertisement

A proposed 1,219-share sale by Arcutis (Nasdaq: ARQT) officer Matsuda follows stock vesting.

https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-0c8da6019855.html
Masaru Matsuda, an officer at Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), has proposed selling 1,219 common shares valued at $38,841.48 through Merrill Lynch, with an approximate sale date of November 2, 2026. These shares were acquired through restricted stock vesting on November 1, 2026. The filing also notes previous sales by Matsuda of 9,989 shares on September 8, 2026, and 3,674 shares on September 16, 2026.

Arcutis Biotherapeutics, Inc. (ARQT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ARQT/seasonality/
This Yahoo Finance page presents a seasonal returns chart for Arcutis Biotherapeutics, Inc. (ARQT), displaying average monthly price returns from 2020 to 2026. The page also shows current stock prices and after-hours trading information for ARQT.

Form 4 Arcutis Biotherapeutics Inc: Robert A. Scott (Director) For: 23 October

https://ng.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-robert-a-scott-director-for-23-october-93CH-2764952
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc., specifically detailing a transaction by Director Robert A. Scott on October 23. Form 4 filings are mandatory SEC documents that disclose changes in the beneficial ownership of securities by a company's officers, directors, and principal stockholders. The article title reiterates the main point of the filing.

Form 4 Arcutis Biotherapeutics Inc: Robert A. Scott (Director) For: 23 October

https://ca.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-robert-a-scott-director-for-23-october-93CH-4911035
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc., indicating a transaction by Robert A. Scott, a Director of the company, on October 23rd. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by its officers, directors, and principal stockholders. The article is a brief news item published by Investing.com.

A director receives options exercisable at $31.20 and rights to 2,819 shares at Arcutis (ARQT).

https://www.stocktitan.net/sec-filings/ARQT/form-4-arcutis-biotherapeutics-inc-insider-trading-activity-434e060867e9.html
Arcutis Biotherapeutics director Robert A. Scott received two stock-option awards on October 23, 2026, totaling 29,170 options, each with a $31.20 exercise price and an expiration date of October 23, 2036. He also received 2,819 restricted stock units (RSUs). The vesting terms vary for each award, subject to his continued service.
Advertisement

Form 8K Arcutis Biotherapeutics Inc For: 28 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-arcutis-biotherapeuticsinc-for-28-october-93CH-2763694
This Investing.com article reports on Arcutis Biotherapeutics Inc.'s Form 8K filing for October 28, 2026. The brief announcement provides no specific details about the content of the 8K filing, but indicates it is a company news item related to stock markets. The article also includes stock market data and other related news from Investing.com.

Arcutis Appoints Rob Scott, MD to Board of Directors

https://www.globenewswire.com/news-release/2026/10/28/3390222/0/en/arcutis-appoints-rob-scott-md-to-board-of-directors.html
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has appointed Rob Scott, MD, a global pharma industry leader with over 40 years of experience, to its Board of Directors. Dr. Scott, formerly Chief Medical Officer at AbbVie, is expected to provide invaluable expertise as Arcutis advances its pipeline of innovative immuno-dermatology therapies. He will contribute to bringing new treatment options to individuals suffering from chronic inflammatory skin diseases.

Form 8K Arcutis Biotherapeutics Inc For: 28 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-arcutis-biotherapeuticsinc-for-28-october-93CH-4909665
Arcutis Biotherapeutics Inc. filed a Form 8K for October 28th, as reported by Investing.com. The article simply notes this filing without providing further details about its content. It also includes various market data and other Investing.com features.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

https://ca.finance.yahoo.com/news/arcutis-biotherapeutics-inc-arqt-reports-130025409.html
Arcutis Biotherapeutics, Inc. (ARQT) is anticipated to report a year-over-year increase in earnings and higher revenues for the quarter ending September 2026, with an expected release on November 4. Analysts project quarterly earnings of $0.17 per share, a 183.3% increase, and revenues of $141.64 million, up 42.8%. The company's positive Earnings ESP and Zacks Rank #3 suggest a high probability of beating the consensus EPS estimate.

Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Momentum Meets a Breakout Setup

https://www.chartmill.com/news/ARQT/Chartmill-57004-Arcutis-Biotherapeutics-NASDAQARQT-High-Growth-Momentum-Meets-a-Breakout-Setup
Arcutis Biotherapeutics (NASDAQ:ARQT) exhibits strong growth momentum and a favorable technical setup, making it a potential breakout candidate. The company shows robust EPS and revenue growth, positive analyst revisions, and a history of beating estimates, alongside a high technical rating and a bullish chart pattern. While some risks like decelerating sales growth and proximity to resistance exist, multiple screens confirm its growth and setup potential.
Advertisement

Arcutis Appoints Rob Scott, MD to Board of Directors

https://www.nasdaq.com/press-release/arcutis-appoints-rob-scott-md-board-directors-2026-10-28
Arcutis Biotherapeutics, Inc. has appointed Rob Scott, MD, a global pharma industry leader with over 40 years of experience, to its Board of Directors, effective October 23, 2026. Dr. Scott, formerly Chief Medical Officer at AbbVie and VP of Global Development at Amgen, will bring extensive expertise in developing and securing approvals for novel medicines, including dermatology and immunology therapies, to support Arcutis's pipeline and growth initiatives. His appointment is expected to be invaluable as Arcutis continues to advance its treatments for chronic inflammatory skin diseases.

Technical Reactions to ARQT Trends in Macro Strategies

https://news.stocktradersdaily.com/news_release/8/Technical_Reactions_to_ARQT_Trends_in_Macro_Strategies_102626033201_1792999921.html
This article provides a technical analysis of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), indicating that strong near and mid-term sentiment could extend to the long term, with compelling upside potential due to a lack of resistance above the current price. It outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis, including support and resistance levels.

Arcutis Biotherapeutics, Inc. Estimates – NASDAQ:ARQT

https://www.tradingview.com/symbols/NASDAQ-ARQT/financials-estimates/
This article provides access to financial actuals and analyst estimates for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) via TradingView. Users can explore reported financial data, compare actual results with estimates, and visualize trends over time across income statements, balance sheets, cash flow statements, and valuation metrics. The information is presented as a tool for research and not as investment advice.

Arcutis Biotherapeutics, Inc. (ARQT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/ARQT/
Arcutis Biotherapeutics, Inc. (ARQT) stock is currently trading at $30.99, down 3.76%, as of 2:44:07 pm GMT-4. The company focuses on developing and commercializing treatments for dermatological diseases, with its lead product being ZORYVE. Analysts have an average 1-year target price of $39.12, with recent ratings including a "Buy" from Guggenheim.

Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026

https://www.manilatimes.net/2026/10/22/tmt-newswire/globenewswire/arcutis-to-report-third-quarter-2026-financial-results-and-host-conference-call-on-november-4-2026/2451199/amp
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced it will report its third quarter 2026 financial results and provide a business update after U.S. financial markets close on Wednesday, November 4, 2026. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day. A live webcast and presentation materials will be available on the "Events" section of the company’s website.
Advertisement

Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $44

https://www.moomoo.com/news/post/1001596179/guggenheim-maintains-arcutis-biotherapeutics-arqtus-with-buy-rating-raises-target
Guggenheim has reiterated its Buy rating for Arcutis Biotherapeutics (ARQT.US) and increased its target price to $44. This indicates a positive outlook from Guggenheim regarding the company's future performance and stock value.

A former officer proposes another Arcutis (ARQT) share sale after an $8.3M sale in September.

https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-b1ad3bef00e1.html
Larry Todd Edwards, a former officer at Arcutis Biotherapeutics, Inc., has proposed selling 60,376 common shares worth approximately $1.99 million, with an approximate sale date of October 20, 2026. This follows previous sales by Edwards, including 4,730 shares on August 17, 2026, and a substantial 341,980 shares totaling over $9.5 million on September 16, 2026. The proposed sale and prior transactions are detailed in an SEC Form 144 filing, outlining the acquisition dates and nature of the securities.

Form 4 Arcutis Biotherapeutics Inc: Howard G. Welgus (Director) For: 15 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-howard-g-welgus-director-for-15-october-93CH-4512897
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc, specifically detailing a transaction made by director Howard G. Welgus on October 15th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by its insiders. The article indicates that further details regarding this transaction would be available within the filing itself.

Form 4 Arcutis Biotherapeutics Inc: Howard G. Welgus (Director) For: 15 October

https://ng.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-howard-g-welgus-director-for-15-october-93CH-2744742
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc, specifically detailing an insider transaction involving director Howard G. Welgus, which occurred on October 15th. The filing is a standard regulatory disclosure indicating changes in company ownership by insiders.

Form 4 Arcutis Biotherapeutics Inc: Howard G. Welgus (Director) For: 15 October

https://au.investing.com/news/stock-market-news/form-4-arcutis-biotherapeuticsinc-howard-g-welgus-director-for-15-october-93CH-4700204
This article reports on a Form 4 filing for Arcutis Biotherapeutics Inc., indicating activity by director Howard G. Welgus on October 15. The brief piece primarily serves as an announcement of this insider transaction, providing no further details on the nature or value of the transaction. It includes general market data and related news alongside the main announcement.
Advertisement

Arcutis Biotherapeutics stock hits 52-week high at $31.80

https://www.investing.com/news/company-news/arcutis-biotherapeutics-stock-hits-52week-high-at-3180-93CH-4958019
Arcutis Biotherapeutics Inc. (ARQT) stock reached a new 52-week high of $31.80, marking a 38% increase over the past year and a nearly 10% rise in the last week. This surge follows strong second-quarter 2026 financial results with net product revenue of $129.9 million, exceeding forecasts, and analysts upgrading earnings estimates. The company's profitability and strong sales of its Zoryve treatment further underscore investor confidence and market sentiment.

Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027

https://finance.yahoo.com/markets/stocks/articles/arcutis-soars-12-guggenheim-lifts-171326281.html
Arcutis shares surged 12% after Guggenheim raised its price target to $44 from $38, maintaining a Buy rating, based on increased confidence in the company's performance by 2027. This follows another bullish call from Cantor Fitzgerald, which initiated coverage with an Overweight rating and a $48 target last week. Analysts anticipate Arcutis's revenue to grow significantly, driven primarily by its Zoryve franchise, with operating leverage expected to expand in 2027 as sales spending moderates.

Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)

https://seekingalpha.com/news/4654399-arcutis-biotherapeutics-advances-11-to-new-52-week-high
Shares of Arcutis Biotherapeutics (ARQT) climbed almost 11% on Monday, reaching a new 52-week high of $31.89. This surge is attributed to optimism surrounding the ZORYVE franchise expansion, strong operating performance, and the company's projected rapid transition to profitability. Analysts note risks such as product concentration, competition, clinical trial outcomes, and payer pressures.

Arcutis Biotherapeutics stock hits 52-week high at $31.80 By Investing.com

https://in.investing.com/news/stock-market-news/arcutis-biotherapeutics-stock-hits-52week-high-at-3180-93CH-5640946
Arcutis Biotherapeutics Inc. (ARQT) stock reached a new 52-week high of $31.77, currently trading at $31.83, reflecting a 38% increase over the past year. This surge is supported by strong Q2 2026 financial results, with net product revenue of $129.9 million, exceeding forecasts, and analysts revising earnings upwards for the upcoming period. The company's impressive 91% gross profit margin and growing demand for its Zoryve treatment also contribute to positive market sentiment.

Arcutis Biotherapeutics (ARQT) Unveiled Fresh ZORYVE Data, Is The Stock Still Below Fair Value?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/arcutis-biotherapeutics-arqt-unveiled-fresh-zoryve-data-is-t
Arcutis Biotherapeutics (ARQT) recently released new data from its ZORYVE portfolio, including positive Phase 2 results for infant atopic dermatitis. Despite a significant 1-year shareholder return of 38.03%, the stock is considered undervalued by many, with a fair value of $38.38 compared to its current price of $28.82. However, concerns exist about its high P/E ratio of 127x, suggesting it might be expensive on earnings if growth falters.
Advertisement

Form 144 Arcutis Biotherapeutics For: 16 October By Investing.com

https://in.investing.com/news/stock-market-news/form-144-arcutis-biotherapeutics-for-16-october-93CH-5636504
This article from Investing.com reports on a Form 144 filing for Arcutis Biotherapeutics, dated October 16. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal detail beyond the filing's existence and date.

Form 144 Arcutis Biotherapeutics For: 16 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-arcutis-biotherapeutics-for-16-october-93CH-4884312
This article reports the filing of Form 144 for Arcutis Biotherapeutics on October 16. It is a brief announcement from Investing.com, providing basic information about the filing and the company's stock symbol, ARQT. The article includes standard financial market data and popular news headlines from the platform.

A director proposes selling 4,728 shares of Arcutis (NASDAQ: ARQT).

https://www.stocktitan.net/sec-filings/ARQT/144-arcutis-biotherapeutics-inc-sec-filing-a8c212e36ce0.html
Howard Welgus, a director at Arcutis Biotherapeutics, Inc. (ARQT), has reported a proposed sale of 4,728 common shares with an aggregate market value of $127,325.04, expected around October 15, 2026. This proposed transaction follows two earlier sales by Welgus of 4,730 shares each in August and September 2026. The Form 144 filing also details the acquisition of these securities through restricted stock vesting and stock option exercises.

(ARQT) Movement as an Input in Quant Signal Sets

https://news.stocktradersdaily.com/news_release/81/ARQT_Movement_as_an_Input_in_Quant_Signal_Sets_101526065201_1792104721.html
This article analyzes Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) using quantitative signals. It identifies strong near-term sentiment with a neutral mid and long-term outlook, noting a current breakout with potential for higher levels due to an absence of resistance. The analysis also provides institutional trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis.

Arcutis CEO Frank Watanabe: Zoryve's $525M Guidance Rests on a Clinician-Led Revolt Against Topical Steroids

https://finance.biggo.com/news/bc9d5dc45fe3eaca
Arcutis Biotherapeutics CEO Frank Watanabe projects Zoryve's substantial revenue guidance on the back of a growing "steroid stewardship" movement, driven by clinicians, that is shifting the market away from traditional topical steroids. He emphasizes Zoryve's strategic pricing for access and the importance of allowing the clinical community to lead the anti-steroid narrative. Watanabe also shares a unique perspective on AI's narrow application at Arcutis, foreseeing its greatest impact in drug discovery.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement